Vactosertib not checked
MedPacto, Inc. · TEW-7197
FollowEvery change as it happens, and a Monday email
Trials
1 active
6 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Vactosertib is given twice a day, five days on and two days off in four-week cycles. Vactosertib is a transforming growth factor-beta (TGF-β) type 1 receptor inhibitor.”In the company’s words, NCT05588648 on ClinicalTrials.gov
- Tested for
- Osteosarcoma
- Main trialPhase 1/2
- “MP-VAC-209 is a Phase I/II, open label, single arm, multi-center study to assess safety, tolerability, and antitumor activity of vactosertib as a single agent in adolescents and adults with recurrent, refractory, or progressive osteosarcoma. Vactosertib is given orally, twice a day, to people 12 years of age and older who meet the criteria for study enrollment.”In the company’s words, NCT05588648 on ClinicalTrials.gov
- Other names
- TEW-7197 · vactosetib
Other drugs for Osteosarcoma
- HS-20093Hansoh · Phase 2
- KC1036Beijing Konruns Pharmaceutical Co., Ltd. · Phase 2
- EntrectinibRoche · Phase 1/2
- LNTH2403Lantheus Medical Imaging · Phase 1/2
- LurbinectedinJazz Pharmaceuticals · Phase 1/2
- SOT106SOTIO Biotech a.s. · Phase 1/2
Coming up1
- Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | Dec 2027 | Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma | |
| Phase 2Withdrawn | 23 May 2022 | Vactosertib and Imatinib Combination in Patients with Advanced Desmoid Tumor/aggressive Fibromatosis (DT/AF) | |
| Phase 1/2Completed | 3 Jan 2022 | TEW-7197 with Paclitaxel for the Treatment of Metastatic Gastric Cancer | |
| Phase 1/2Completed | 7 May 2024 | Vactosertib in Combination with Pembrolizumab in Metastatic Colorectal or Gastric Cancer | |
| Phase 1/2Completed | 17 May 2024 | Phase 1b/2a, Open-label Study of Vactosertib in Combination With Durvalumab in Advanced NSCLC | |
| Phase 1Completed | 31 Dec 2019 | Dose Escalation and Proof-of-Concept Studies of Vactosertib (TEW-7197) Monotherapy in Patients With MDS |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026